Collaborative research uncovers immune and biomarker patterns that could help subclassify ME/CFS and guide future treatments.

Sample analysis, including deep immune profiling was performed by Dr. Akiko Iwasaki and team at Yale University.
Medford MA – May 16, 2025 – A PolyBio-supported study published today in the Journal of Immunology sheds new light on the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) disease process. This includes the identification of two biologically distinct ME/CFS subgroups based on cerebrospinal fluid (CSF) markers. The research was performed by a collaborative team of researchers connected via PolyBio Research Foundation. Primary analysis occurred at Dr. Akiko Iwasaki’s Yale University laboratory, with study samples obtained at the Bragee Clinic in Sweden. PolyBio co-founders Dr. Amy Proal and Dr. Michael VanElzakker facilitated the collaboration and helped with data interpretation and contextualization.
More specifically, the team performed comprehensive immune profiling on blood and CSF collected from individuals with ME/CFS. They measured cytokine and hormone levels, pathogen protein antibody responses, and autoantibody profiles in patient samples. They identified two distinct immunotypes within the ME/CFS cohort based on CSF matrix metalloproteinase (MMP) levels. One subgroup (Cluster 1) exhibited elevated levels of MMP-1, MMP-2, and MMP-10, as well as increased concentrations of several cytokines. These markers may reflect a disease variant driven by central nervous system inflammation. The other subgroup (Cluster 2) showed distinct correlations between immune markers and higher rates of joint hypermobility.

The study identified two distinct ME/CFS clusters or immunotypes.
Interestingly, while the clinical symptoms between these clusters were similar, seropositivity patterns differed: Cluster 1 had greater exposure to cytomegalovirus, while Cluster 2 had more frequent exposure to SARS-CoV-2 and parvovirus B19. The study also noted changes in specific immune pathways. ME/CFS participants showed altered cytokine correlation patterns, including disrupted interactions involving fractalkine—a chemokine involved in neuron-microglia communication—and eotaxin, a molecule implicated in aging and neurodegeneration. These disturbances may influence neuroinflammation and symptom development.
Autoantibody analysis revealed no major differences in IgG autoantibodies between ME/CFS and control participants. However, a general reduction in IgM autoantibody reactivity, including a decrease in anti-factor P IgM, was observed in ME/CFS patients, raising questions about the role of immune regulation in the disease.
The authors stress that while ME/CFS patients often present with similar clinical profiles, deep immune profiling reveals key biological differences that could be crucial for personalized treatment development. In other words, different ME/CFS patients with different subtypes of the disease may respond to different medications, which could be key in helping MDs optimally manage care for patients with the diagnosis. Indeed, further research must continue to search objective biomarkers to help classify ME/CFS into meaningful subgroups.
The research team also advocates for future studies designed to collect tissue biopsy samples from ME/CFS patients, which could help determine if persistent reservoirs of pathogens – such as the herpesviruses and enteroviruses – could contribute to some of the immune or MMP alterations observed in the study.
Overall the findings mark a significant step forward in unraveling the heterogeneity of ME/CFS and lays the groundwork for precision medicine approaches to treating the debilitating condition.
